iBio (IBIO) Short Interest Ratio & Short Volume

Short interest is the volume of iBio shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 850,900 shares of IBIO short. 9.14% of iBio's shares are currently sold short. Learn More on iBio's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IBIO shares currently have a short interest ratio of 2.0. Learn More on iBio's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.14% of iBio's floating shares are currently sold short.

iBio saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 850,900 shares, a decrease of 5.7% from the previous total of 902,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

iBio currently has issued a total of 3,480,000 shares. Some of iBio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. iBio currently has a public float of 9,310,000 shares.

9.14% of iBio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to iBio: Gain Therapeutics, Inc. (1.30%), Metagenomi, Inc. (12.07%), Pyxis Oncology, Inc. (15.81%), Inozyme Pharma, Inc. (9.16%), Context Therapeutics Inc. (5.42%), Janone Inc. (2.03%), Ikena Oncology, Inc. (1.10%), Cue Biopharma, Inc. (1.55%), Achilles Therapeutics plc (1.26%), Applied Therapeutics, Inc. (17.11%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

Short selling IBIO is an investing strategy that aims to generate trading profit from iBio as its price is falling. IBIO shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for iBio occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IBIO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IBIO, twice per month. The most recent reporting period available is March, 15 2025.